1 row where names contains "Alberto Daniele"
✎ View and edit SQL
Suggested facets: created (date), title (array), award_numbers (array), funder_names (array), funder_dois (array)
names (array) ✖
|11||11||["Ovarian Cancer in Elderly Patients: Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index"]||10.1097/igc.0000000000001097||http://dx.doi.org/10.1097/igc.0000000000001097||2017-08-01T21:01:48Z||||28||10||["1048-891X", "1525-1438"]||International Journal of Gynecologic Cancer||<jats:sec><jats:title>Objective</jats:title><jats:p>The present study assessed the predictive value of age and Modified Frailty Index (mFI) on the management of primary epithelial ovarian cancer (EOC) patients aged 70 years or older (elderly).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A retrospective multicenter study selected elderly EOC patients treated between 2006 and 2014. Treatments were analyzed according to the following age group categories: (1) 70 to 75 years versus (2) older than 75 years, and mFI of less than 4 (low frailty) versus greater than or equal to 4 (high frailty).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Seventy-eight patients were identified (40 in age group 1 and 38 in age group 2). The mFI was greater than or equal to 4 in 23 women. Median age of low frailty and high frailty was not significantly different (75.6 vs 75.3). Comorbidities were equally distributed according to age, whereas diabetes, hypertension, obesity, and chronic renal failure were more frequent in the high-frailty group. Performance status was different only according to mFI. Twenty percent of age group 1 versus 55.3% of age group 2 underwent none or only explorative surgical approach (<jats:italic>P</jats:italic> = 0.003), whereas surgical approaches were similar in the 2 frailty groups. The rate of postoperative complications was higher in high-frailty patients compared with low-frailty patients (23.5% vs 4.3%; <jats:italic>P</jats:italic> = 0.03). Chemotherapy was administered to all the patients, a monotherapy regimen to 50% of them. No differences in toxicity were registered, except more hospital recovery in the high-frailty cohort. Median survival time was in favor of younger patients (98 versus 30 months) and less-frailty patients (56 vs 27 months).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Elderly EOC patients can receive an adequate treatment, but patients who are older than 75 years can be undertreated, if not adequately selec…||8||||["Annamaria Ferrero", "Luca Fuso", "Elisa Tripodi", "Roberta Tana", "Alberto Daniele", "Valentina Zanfagnin", "Stefania Perotto", "Angiolo Gadducci"]||[""]||[""]||[""]|
CREATE TABLE [article] ( [title] TEXT, [DOI] TEXT, [URL] TEXT, [created] TEXT, [subject] TEXT, [references-count] TEXT, [is-referenced-by-count] TEXT, [ISSN] TEXT, [container-title] TEXT, [abstract] TEXT, [author_number] TEXT, [orcids] TEXT, [names] TEXT, [award_numbers] TEXT, [funder_names] TEXT, [funder_dois] TEXT );